Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

Director Bethany Sensenig reports the cancellation and cash conversion of stock options following the completed merger of KalVista Pharmaceuticals into Chiesi Farmaceutici.

Summary

• KalVista Pharmaceuticals, Inc. has been acquired by Chiesi Farmaceutici S.p.A. via a merger transaction effective June 11, 2026.
• The acquisition was executed through a cash tender offer at a price of $27.00 per share.
• Reporting person Bethany Sensenig held 45,000 stock options with an exercise price of $12.05.
• These options were cancelled and converted into a cash payment representing the difference between the $27.00 merger consideration and the $12.05 exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event as it represents the final administrative step of a completed corporate acquisition.

Positives

• Shareholders received a cash exit at $27.00 per share.
• Option holders with exercise prices below the merger consideration received a cash payout for their equity interest.

Negatives

• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Chiesi Farmaceutici.
• Options with an exercise price equal to or greater than the $27.00 merger consideration were cancelled for no consideration.

Risks

• The company has ceased to exist as an independent public entity, eliminating future investment opportunities in the stock.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Chiesi Farmaceutici; therefore, no further public guidance or forward-looking statements are applicable.

Management Comments

• The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their pipelines, particularly in rare disease or specialized therapeutic areas.

Comparison to Industry Standards

• The $27.00 cash-out price represents the final valuation for public shareholders following the completion of the tender offer.
• The treatment of 'in-the-money' options is consistent with standard change-of-control provisions in pharmaceutical M&A agreements.

Stakeholder Impact

• Shareholders have been cashed out at the agreed merger price.
• Employees and management transition to being part of a subsidiary of Chiesi Farmaceutici.

Next Steps

• Delisting of KalVista Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

KalVista Pharmaceuticals, Merger, Acquisition, Chiesi Farmaceutici, Form 4, Insider Transaction